Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.050
-0.050 (-1.61%)
At close: Aug 10, 2026, 4:00 PM EDT
2.760
-0.290 (-9.51%)
After-hours: Aug 10, 2026, 7:27 PM EDT
Evaxion Employees
Evaxion had 46 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
46
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$163,652
Profits / Employee
-$212,087
Market Cap
25.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 46 | 0 | - |
| Dec 31, 2024 | 46 | -3 | -6.12% |
| Dec 31, 2023 | 49 | -14 | -22.22% |
| Dec 31, 2022 | 63 | 2 | 3.28% |
| Dec 31, 2021 | 61 | 26 | 74.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Longeveron | 38 |
| Quince Therapeutics | 38 |
| Kyntra Bio | 34 |
| Actinium Pharmaceuticals | 25 |
| ABVC BioPharma | 19 |
| Tevogen | 18 |
| Barinthus Biotherapeutics | 14 |
EVAX News
- 10 hours ago - Merck discloses 1.21M share holding in Evaxion Biotech - TheFly
- 24 days ago - Evaxion Biotech to present EVX-01 clinical efficacy data at ESMO - TheFly
- 24 days ago - Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 - GlobeNewsWire
- 4 weeks ago - Evaxion Biotech presents new data on EVX-V1 - TheFly
- 4 weeks ago - Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 - GlobeNewsWire
- 5 weeks ago - Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop - GlobeNewsWire
- 2 months ago - Evaxion receives Prix Galien UK Award for Best digital health solution - GlobeNewsWire
- 2 months ago - Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - GlobeNewsWire